Relaunch of the Innovative Licensing and Access Pathway (ILAP)

ILAP is focussed on getting the most transformative new medicines to patients more quickly. It is a unique initiative delivered in collaboration by:

  • the UK regulator: Medicines and Healthcare products Regulatory Agency (MHRA),
  • the UK health technology assessment bodies: All Wales Therapeutics and Toxicology Centre (AWTTC), National Institute for Health and Care Excellence (NICE), Scottish Medicines Consortium (SMC) and
  • the NHS.

For more information on the relaunch visit Statement of policy intent: relaunch of the Innovative Licensing and Access Pathway - GOV.UK

About us

Back to latest updates